Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
OBJECTIVE: This study aimed to analyze the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 proliferation index in the brain metastatic lesions and primary lesions in Chinese patients with breast cancer brain metasta...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637832/ https://www.ncbi.nlm.nih.gov/pubmed/36353124 http://dx.doi.org/10.3389/fneur.2022.1002173 |
_version_ | 1784825268757594112 |
---|---|
author | Jiaxin, Chen Jinmei, Zhou Huiqiang, Zhang Xuexue, Wu Xiaobo, Wang Shaohua, Zhang Yanhong, Tai Zefei, Jiang Tao, Wang |
author_facet | Jiaxin, Chen Jinmei, Zhou Huiqiang, Zhang Xuexue, Wu Xiaobo, Wang Shaohua, Zhang Yanhong, Tai Zefei, Jiang Tao, Wang |
author_sort | Jiaxin, Chen |
collection | PubMed |
description | OBJECTIVE: This study aimed to analyze the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 proliferation index in the brain metastatic lesions and primary lesions in Chinese patients with breast cancer brain metastasis (BCBM) and determine the correlation between their changes and patients' survival. METHODS: A retrospective analysis was performed on patients with BCBM. The clinical characteristic of these patients was collected. The differences in the expression levels of the ER, PR, HER-2, and Ki-67 index between the primary lesions and brain lesions were evaluated, and the association between the differences and survival was analyzed. RESULTS: The conversion rate of anyone receptor (ER, PR, or HER2) between the primary lesions and brain metastatic lesions was 45.0% (18/40), of which the ER inconsistency rate was 25.0%, the PR inconsistency rate was 22.5%, and the HER-2 inconsistency rate was 15.0%, and the receptor conversion resulted in a subtype conversion of 27.5% (11/40). The patients with HER-2 expression discordance between the primary lesions and the brain metastatic lesions had significantly longer survival times (58.9 vs. 26.4 months, P = 0.04) after diagnosis of brain metastases. CONCLUSION: In this study, 45.0% of breast cancer patients developed biomarker-conversion between the primary lesions and brain metastatic lesions, and the differences in the expression levels of the ER, PR, and HER-2, the change in Ki-67 index between the primary lesions and brain lesions may predict patients' survival. |
format | Online Article Text |
id | pubmed-9637832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96378322022-11-08 Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain Jiaxin, Chen Jinmei, Zhou Huiqiang, Zhang Xuexue, Wu Xiaobo, Wang Shaohua, Zhang Yanhong, Tai Zefei, Jiang Tao, Wang Front Neurol Neurology OBJECTIVE: This study aimed to analyze the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 proliferation index in the brain metastatic lesions and primary lesions in Chinese patients with breast cancer brain metastasis (BCBM) and determine the correlation between their changes and patients' survival. METHODS: A retrospective analysis was performed on patients with BCBM. The clinical characteristic of these patients was collected. The differences in the expression levels of the ER, PR, HER-2, and Ki-67 index between the primary lesions and brain lesions were evaluated, and the association between the differences and survival was analyzed. RESULTS: The conversion rate of anyone receptor (ER, PR, or HER2) between the primary lesions and brain metastatic lesions was 45.0% (18/40), of which the ER inconsistency rate was 25.0%, the PR inconsistency rate was 22.5%, and the HER-2 inconsistency rate was 15.0%, and the receptor conversion resulted in a subtype conversion of 27.5% (11/40). The patients with HER-2 expression discordance between the primary lesions and the brain metastatic lesions had significantly longer survival times (58.9 vs. 26.4 months, P = 0.04) after diagnosis of brain metastases. CONCLUSION: In this study, 45.0% of breast cancer patients developed biomarker-conversion between the primary lesions and brain metastatic lesions, and the differences in the expression levels of the ER, PR, and HER-2, the change in Ki-67 index between the primary lesions and brain lesions may predict patients' survival. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9637832/ /pubmed/36353124 http://dx.doi.org/10.3389/fneur.2022.1002173 Text en Copyright © 2022 Jiaxin, Jinmei, Huiqiang, Xuexue, Xiaobo, Shaohua, Yanhong, Zefei and Tao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Jiaxin, Chen Jinmei, Zhou Huiqiang, Zhang Xuexue, Wu Xiaobo, Wang Shaohua, Zhang Yanhong, Tai Zefei, Jiang Tao, Wang Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title | Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title_full | Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title_fullStr | Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title_full_unstemmed | Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title_short | Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain |
title_sort | conversion of er, pr, her2 and ki-67 and prognosis in breast cancer metastases to the brain |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637832/ https://www.ncbi.nlm.nih.gov/pubmed/36353124 http://dx.doi.org/10.3389/fneur.2022.1002173 |
work_keys_str_mv | AT jiaxinchen conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT jinmeizhou conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT huiqiangzhang conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT xuexuewu conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT xiaobowang conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT shaohuazhang conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT yanhongtai conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT zefeijiang conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain AT taowang conversionoferprher2andki67andprognosisinbreastcancermetastasestothebrain |